Clinical Trials Directory

Trials / Completed

CompletedNCT00362271

Aripiprazole and Effexor XR Drug Interaction Study

Effects of Aripiprazole on the Steady-State Pharmacokinetics of Venlafaxine in Healthy Subjects

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
38 (planned)
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc. · Industry
Sex
All
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

The purpose of this clinical research study is to learn whether aripiprazole has effect on the steady-state pharmacokinetics of venlafaxine in healthy subjects. The safety and tolerability of aripiprazole and venlafaxine co-administration will also be studied.

Conditions

Interventions

TypeNameDescription
DRUGVenlafaxine on Day -4 to day 14, Aripiprazole dosed starting on Day 1: 3 days at 10 mg, 4 days at 1 mg and 7 days at 20 mg.Tablets, Oral, Venlafaxine: 75 mg; Aripiprazole: 10, 15, 20 mg once daily, 14 days.

Timeline

Start date
2006-08-01
Primary completion
2006-09-01
Completion
2006-09-01
First posted
2006-08-09
Last updated
2013-11-08

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00362271. Inclusion in this directory is not an endorsement.